Pavel A. Isaev

Obninsk, KLU, Russian Federation

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.

INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: January 10, 2025

Indocyanine green angiography in assessment of parathyroid remnant perfusion after subtotal parathyroidectomy: a case report

Indocyanine green angiography in assessment of parathyroid remnant perfusion after subtotal parathyroidectomy: a case report

Journal: Khirurgiia

Published: February 21, 2024

Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer.

Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer.

Journal: The New England journal of medicine

Published: October 23, 2023

Indocyanine green fluorescence angiography in transoral endoscopic thyroidectomy for papillary thyroid cancer

Indocyanine green fluorescence angiography in transoral endoscopic thyroidectomy for papillary thyroid cancer

Journal: Khirurgiia

Published: September 08, 2023

Preventive Transoral Endoscopic Thyroidectomy by Vestibular Approach in 6-Year-Old Patient with the High-Risk RET C634R Germline Mutation.

Preventive Transoral Endoscopic Thyroidectomy by Vestibular Approach in 6-Year-Old Patient with the High-Risk RET C634R Germline Mutation.

Journal: Case reports in oncology

Published: June 02, 2023

A Randomized, Double-Blind Noninferiority Study to Evaluate the Efficacy of the Cabozantinib Tablet at 60 mg Per Day Compared with the Cabozantinib Capsule at 140 mg Per Day in Patients with Progressive, Metastatic Medullary Thyroid Cancer.

A Randomized, Double-Blind Noninferiority Study to Evaluate the Efficacy of the Cabozantinib Tablet at 60 mg Per Day Compared with the Cabozantinib Capsule at 140 mg Per Day in Patients with Progressive, Metastatic Medullary Thyroid Cancer.

Journal: Thyroid : official journal of the American Thyroid Association

Published: April 11, 2022

Isolated neurofibroma of the tongue

Isolated neurofibroma of the tongue

Journal: Stomatologiia

Published: April 20, 2021

Clinical, morphological, and prognostic features of papillary thyroid carcinoma with different BRAF mutational status assessed by immunohistochemistry

Clinical, morphological, and prognostic features of papillary thyroid carcinoma with different BRAF mutational status assessed by immunohistochemistry

Journal: Arkhiv patologii

Published: June 22, 2018

TREATMENT OF LOCAL RADIATION LESIONS IN BREAST CANCER PATIENTS.

TREATMENT OF LOCAL RADIATION LESIONS IN BREAST CANCER PATIENTS.

Journal: Voprosy onkologii

Published: January 01, 2016

Prognostic value of hemoglobin concentration in the course of chemoradiotherapy of patients with oropharyngeal squamous cell carcinoma

Prognostic value of hemoglobin concentration in the course of chemoradiotherapy of patients with oropharyngeal squamous cell carcinoma

Journal: Voprosy onkologii

Published: May 29, 2015

Radiation therapy for medullary thyroid carcinoma

Radiation therapy for medullary thyroid carcinoma

Journal: Voprosy onkologii

Published: January 01, 2013

Immediate and long-term results of simultaneous chemoradiotherapy in non-traditional modes of fractionation in the treatment of patients with oropharyngeal squamous cell carcinoma

Immediate and long-term results of simultaneous chemoradiotherapy in non-traditional modes of fractionation in the treatment of patients with oropharyngeal squamous cell carcinoma

Journal: Voprosy onkologii

Published: January 01, 2013

Showing 1-12 of 12

Last Updated: 09/26/2026